Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · •The addition of pembrolizumab to taxane-platinum–based chemotherapy followed by an anthracycline significantly increased pathologic complete response (pCR) rates and improved event-free survival in early-stage high-risk TNBC.
15 Φεβ 2023 · Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy.
In patients with TNBC stage I–II after RM and adjuvant radiation therapy, the overall incidence of local recurrence was 2%, lymphatic metastasis – 3.4%, distant metastases – 9.0%, 7.4% of patients died. The five-year survival rate was 95.5% .
9 Νοε 2021 · In unselected patients with TNBC, the addition of anti-PD-1/PD-L1 antibodies to neoadjuvant chemotherapy increased the pCR rate by 2.8–17% 175,176,177,184. Whether the heterogeneity of these...
29 Μαΐ 2024 · The treatment landscape for early-stage TNBC has changed considerably in the last decade, with new additions to neoadjuvant therapy (NAT) aimed at improving pathologic responses and outcomes. In this study, we assess real world data regarding treatment and outcomes in those with early-stage TNBC.
14 Αυγ 2024 · The Neo-Real study (GBECAM-0123) is a real-world data effort evaluating patients with TNBC treated with neoadjuvant P + CT in ten cancer centers since July 2020. The objective of this analysis...
29 Αυγ 2022 · A new study (Impassion031, NCT03197935) on atezolizumab combined with chemotherapy in early-stage TNBC has shown significantly improved pCR rates. The pCR was 58% (95/165) in the atezolizumab group and 41% (69/168) in the placebo and chemotherapy groups.
